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heparin exposure or preceding infection. Both patients tested strongly positive for anti-PF4/heparin IgG in two different immunoassays, and in the platelet serotonin-release assay. Crucially, both patients' sera also caused strong (>80%) serotonin-release in the absence of heparin, a serologic feature characteristic of "delayed-onset" HIT (i.e., where heparin use precedes HIT but is not required for subsequent development of thrombocytopenia). We propose that a rigorous definition of spontaneous HIT syndrome should include otherwise unexplained thrombocytopenia/thrombosis without proximate heparin exposure, and with anti-PF4/heparin IgG antibodies that cause strong in-vitro platelet activation even in the absence of heparin.
Introduction
Heparin-induced thrombocytopenia (HIT) is a transient, autoimmune-like, prothrombotic disorder caused by platelet-activating IgG reactive against the self protein, platelet factor 4 (PF4) bound to heparin. 1, 2 Rarely, a brief exposure to heparin triggers this adverse reaction beginning after stopping heparin ("delayed-onset HIT"); such patients' sera activate platelets strongly in-vitro even in the absence of pharmacologic heparin. 3 Previous reports [4] [5] [6] [7] suggest that an analogous syndrome can occur without preceding heparin exposure ("spontaneous" HIT syndrome or "autoimmune" HIT). We now report two new cases of spontaneous HIT syndrome, review the literature, and propose a clinical-pathological definition of this disorder including characteristic in-vitro platelet activation features. We also suggest that the existence of spontaneous HIT syndrome following orthopedic surgery confounds interpretation of fondaparinux-associated HIT reported in that patient population. [8] [9] [10] [11] [12] Echocardiographic saline-bubble contrast study revealed no abnormalities. UFH treatment resulted in further platelet count fall to 37×10 9 /L (nadir). Subsequent treatment with argatroban followed by fondaparinux was associated with gradual platelet count recovery to >150×10 9 /L by day 39.
Case Reports and Methods
Patient/control sera were tested for PF4-dependent antibodies using three enzymeimmunoassays (EIAs): an in-house IgG-specific EIA 13 and two commercial (Immucor GTI Diagnostics, Waukesha, WI)-one IgG-specific ("Lifecodes PF4 IgG"), 13 the other a polyspecific EIA detecting IgG/IgA/IgM ("Lifecodes PF4 Enhanced"). 14 We also performed the platelet serotonin-release assay (SRA), as described. 15 Both patients provided informed consent to report their cases. This study was conducted in accordance with the Declaration of Helsinki.
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Results and Discussion
Both patients' admission sera tested strongly-positive for HIT antibodies by all three EIAs, and in the SRA. Moreover, both patients' admission sera (obtained before heparin administration) caused strong platelet activation at 0.1 and 0.3 IU/mL UFH (100% serotonin-release), as well as in the absence of heparin (>80% serotonin-release), with no platelet activation at 100 IU/mL heparin ( Table 1) . Heparin-dependent platelet activation was confirmed using diluted patient sera (see Table legend ). Similar serological features have been reported for patients with delayed-onset HIT 3 as well as in our initial report 4 describing spontaneous HIT syndrome. Antibody reactivity declined markedly by two to four weeks (including disappearance of platelet-activating properties at 0 IU/mL heparin), in keeping with the usual transience of HIT antibodies, 16 and paralleling both patients' platelet count recovery. Laboratory testing did not support a diagnosis of antiphospholipid syndrome (APS) in either patient (see Table legend ) (both APS and spontaneous HIT syndrome are potential explanations for "thrombotic storm" 17 ).
These two cases further support spontaneous HIT syndrome as an unusual explanation for acute thrombosis and thrombocytopenia. Preceding orthopedic surgery is a possible trigger of these antibodies, as per patient 2 (present report) and as previously reported. [5] [6] [7] Indeed, of the seven previously reported cases of spontaneous HIT syndrome in which patients presented with thrombocytopenia and thrombosis in the absence of proximate heparin exposure, five occurred post-orthopedic surgery (all with warfarin anticoagulation given post-knee replacement surgery), whereas the remaining two cases occurred post-infection. In patient 1 (present report), however, we could not identify a potentially causal proximate event. Including our two new cases (present report), plus 6 two previously reported cases (patients 1 and 2 in our initial report 4 Spontaneous HIT syndrome should not be confused with a related clinical picture resembling rapid-onset HIT triggered by therapeutic-dose heparin administration in which, however, no preceding heparin exposure can be identified, yet the patients have circulating anti-PF4/heparin antibodies. This situation has been documented in two patients 4, 18 (without previous heparin exposure) who initially presented with normal platelet counts but then developed acute thrombocytopenia upon receiving therapeuticdose low-molecular-weight heparin 4 or UFH. 18 Importantly, neither serum caused platelet activation at 0 IU/mL heparin, consistent with serum-induced platelet activation that occurs in the absence of heparin (i.e., at buffer control) being important in explaining spontaneous HIT syndrome that presents with thrombocytopenia.
We believe our observations could also have relevance to the understanding of the pathogenesis of fondaparinux-associated HIT. To date, six relatively well-documented cases of HIT following fondaparinux thromboprophylaxis have been reported, [8] [9] [10] [11] [12] without any apparent preceding heparin exposure. Notably, five of the six patients had preceding orthopedic surgery (all but one post-knee replacement), raising the possibility that fondaparinux could be an innocent bystander, i.e., the orthopedic surgery itself could have been the trigger of the subsequent anti-PF4/heparin immune response. Indeed, only
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From minor enhancement of platelet activation in-vitro in the presence of fondaparinux has been observed in these patients. 10, 12 It is plausible that non-heparin triggers of the anti-PF4/heparin immune response, such as glycosaminoglycans released during orthopedic surgery, or bacterial antigens in the case of preceding infection, could account for these unusual clinical observations (bacterial cell walls 19 and RNA/DNA nucleotides 20 bind to PF4, recapitulating HIT antigens, and murine 19 and human bacterial infection 21 are associated with anti-PF4/heparin antibody formation).
We propose that a definitive diagnosis of spontaneous HIT syndrome should be based upon the following criteria: thrombocytopenia (without alternate explanation), thrombosis, lack of proximate heparin exposure, strong-positive PF4-dependent EIAs (at least two different assays), a strong-positive platelet activation assay (>80% peak serotonin-release) featuring strong heparin-independent platelet activation (>50% serotonin-release at 0 IU/mL heparin), as well as heparin-dependent platelet activation (evident upon serum dilution), and exhibiting also the other characteristic features of HIT sera (inhibition at 100 IU/mL heparin and with Fc receptor-blocking monoclonal antibody). Although fulfilling all of these aforementioned criteria will require serum referral for specialized laboratory investigations (namely, the SRA or another functional assay such as the heparin-induced platelet activation test, 22 performed using neat and diluted serum and also including buffer control), initial treatment for presumptive spontaneous HIT syndrome need not be delayed; moreover, our proposed rigorous definition will avoid potential over-diagnosis that could occur if a positive EIA alone was used to detect anti-PF4/heparin antibodies in a patient who presented with otherwise unexplained thrombocytopenia. * For both patients, % serotonin-release was inhibited to 0% at 0.3 IU/mL UFH with Fc receptor-blocking monoclonal antibody (not shown). † Day 0 represents day of admission, with blood sample obtained before any administration of heparin. ‡ Heparin-dependent platelet activation was evident using 1/4 diluted serum: 37% serotonin-release at 0.1 IU/mL UFH versus 0% release at 0 IU/mL heparin (insufficient serum was available to test at 1/2 diluted serum). § Heparin-dependent platelet activation was evident using 1/8 diluted serum (94% serotonin-release at 0.1 IU/mL UFH versus 18% serotoninrelease at 0 IU/mL heparin) and using 1/16 diluted serum (85% serotonin-release at 0.1 IU/mL UFH versus 3% release at 0 IU/mL UFH). ** For patient 2, subsequent results in the EIA-IgG/A/M (Immucor GTI) were: 0.95 (day 100) and 0.25 (day 240). For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
